Biocon secures Health Canada approval for Yesintek autoinjector pen
Biocon secured Health Canada’s Notice of Compliance for Yesintek® ustekinumab autoinjector pen, available in 45 mg/0.05 mL and 90 mg/mL dosages. Approved on July 29, 2026, this new format complements existing prefilled syringes and IV solutions, providing patients with a convenient self-administration option for autoimmune diseases like psoriasis and Crohn’s disease. The move strengthens Biocon’s competitive position in the Canadian biosimilar market.
*this image is generated using AI for illustrative purposes only.
Biocon has secured Notice of Compliance (NOC) from Health Canada for its Yesintek® (ustekinumab) Autoinjector Pen, expanding its biosimilar portfolio in the Canadian market. The approval, announced on July 29, 2026, covers two dosage strengths: 45 mg/0.05 mL and 90 mg/mL. This regulatory milestone adds a convenient self-administration option to Biocon’s existing Yesintek offerings, which include prefilled syringes, vials, and intravenous infusion solutions approved in October 2025. The autoinjector format provides a delivery method not currently offered by the originator product in Canada, allowing for customized treatment approaches across various care settings.
Regulatory Approval Details
The Health Canada approval specifically targets the autoinjector pen formulation of ustekinumab, a biologic therapy used to manage autoimmune conditions. This addition complements the company’s previously approved Yesintek® formulations, including the 45 mg/0.5 mL and 90 mg/mL prefilled syringes and vials, as well as the 130 mg/26 mL intravenous solution. The expansion into autoinjector technology enhances patient convenience and adherence by enabling self-administration.
| Parameter: | Details |
|---|---|
| Regulatory Authority: | Health Canada |
| Product Name: | Yesintek® |
| Active Ingredient: | Ustekinumab |
| Formulation: | Autoinjector Pen |
| Dosage Strengths: | 45 mg/0.05 mL, 90 mg/mL |
| Approval Date: | July 29, 2026 |
Clinical Indications and Market Impact
Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis in adult and pediatric patients aged 6 to 17 years. It also treats active psoriatic arthritis in adults, as well as moderately to severely active Crohn’s disease and ulcerative colitis in adults. These autoimmune conditions affect thousands of Canadians, and the availability of an affordable biosimilar alternative strengthens patient access to care. The new autoinjector format addresses a gap in the Canadian market where the originator product does not offer this delivery mechanism, potentially influencing prescribing patterns and patient preference.
Strategic Significance for Biocon
This approval reinforces Biocon’s commitment to expanding its immunology portfolio in regulated markets like Canada. By diversifying its delivery formats, Biocon aims to provide healthcare providers with more flexible treatment options. The company’s spokesperson noted that this development reaffirms its global mission to increase access to affordable medicines. With a growing presence in North America, Biocon continues to leverage its biosimilar expertise to compete with originator biologics, offering cost-effective solutions without compromising efficacy or safety.
Historical Stock Returns for Biocon
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.29% | -0.92% | -5.87% | +4.47% | +13.40% | +16.80% |
How might the introduction of a self-administered autoinjector format influence Biocon's market share against originator biologics in the Canadian autoimmune treatment sector?
What is the projected timeline for Biocon to seek similar regulatory approvals for the Yesintek autoinjector in other major markets such as the US or EU?
Will this new delivery mechanism trigger specific reimbursement negotiations with Canadian provincial health plans, and how might that impact pricing strategies?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
